Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Total Current Liabilities (2016 - 2025)

Kiora Pharmaceuticals' Total Current Liabilities history spans 11 years, with the latest figure at $3.6 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 39.56% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $3.6 million, down 39.56%, while the annual FY2025 figure was $3.6 million, 39.56% down from the prior year.
  • Total Current Liabilities reached $3.6 million in Q4 2025 per KPRX's latest filing, up from $2.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $6.0 million in Q4 2024 to a low of $212281.0 in Q2 2021.
  • Average Total Current Liabilities over 5 years is $2.6 million, with a median of $2.2 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: plummeted 73.98% in 2021, then soared 1245.69% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $1.6 million in 2021, then surged by 86.03% to $3.0 million in 2022, then tumbled by 45.43% to $1.6 million in 2023, then skyrocketed by 267.73% to $6.0 million in 2024, then plummeted by 39.56% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Total Current Liabilities are $3.6 million (Q4 2025), $2.6 million (Q3 2025), and $3.2 million (Q2 2025).